AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00625651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified FOLFOX6
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
Study NCT00625651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
Study NCT00625651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
Study NCT00450541 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Four questionnaires taking 15-20 minutes total to complete.
Study NCT00450541 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting about 30 minutes.
Study NCT00222872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid Hormone-related Protein
Description: PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
Study NCT00222872 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
Study NCT02839889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxegol
Description: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Study NCT02839889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for two weeks, followed by two week open-label period
Study NCT03058575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary MACs
Description: All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement
Study NCT03058575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No Intervention for 8 weeks
Study NCT05624905 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: Percutaneous Coronary Intervention Procedure
Study NCT00573053 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation range
Description: Maintain functional oxygen saturation range between 91 and 95%
Study NCT00573053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation range
Description: Maintain functional arterial oxygen saturations in the range of 85- 89%
Study NCT02387190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing monitoring
Description: The telenursing program protocol is based on:~1. Contact the patient by telephone, weekly;~2. Distribution and explanation of the educational booklet;~3. Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
Study NCT01241825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trident sugarless chewing gum.
Description: Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
Study NCT01241825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: One control group (these do not chew gum).
Description: The control group will not chew chewing gum while undergoing capsule endoscopy
Study NCT01109680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Multiple dose Neramexane followed by single dose 14C Neramexane
Study NCT03055429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Scale Unit
Description: Pre-test, usability, post-test
Study NCT02790827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA
Description: CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
Study NCT02790827 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
Study NCT04346459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through Fastrach - Group A
Description: Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device
Study NCT04346459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through I-gel - Group B
Description: Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope
Study NCT04346459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through Protector - Group C
Description: Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope
Study NCT02318459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval training-HIIT
Description: HIIT 4 times a week, 30 minutes duration
Study NCT02318459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditionnal group rehabilitation
Description: Traditionnal group rehabilitation, 3 times a week, 1 hour duration
Study NCT02585453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Gel Drops
Description: Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
Study NCT03391817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation administered in gastroscopy
Study NCT03391817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation administered in gastroscopy
Study NCT03921385 — intervention group
Intervention type: DEVICE
Intervention: Augmented Reality Headset
Description: Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
Study NCT02473705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil and Bicarbonate
Description: 1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
Study NCT02473705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil and Bicarbonate Placebo
Description: 1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
Study NCT02473705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil Placebo and Bicarbonate
Description: Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
Study NCT02473705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil Placebo and Bicarbonate Placebo
Description: Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
Study NCT02815943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biliopancreatic diversion with duodenal switch
Study NCT02815943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Study NCT02815943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid meal
Description: will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
Study NCT02815943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: liquid meal
Description: will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
Study NCT02815943 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/scan
Description: a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
Study NCT02815943 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: PET/scan
Description: a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
Study NCT02815943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [7,7,8,8-2H]-palmitate
Description: i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.
Study NCT02815943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [7,7,8,8-2H]-palmitate
Description: i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.
Study NCT02815943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indirect calorimetry
Description: will be performed every hour throughout the protocol along with exhaled breath collection
Study NCT02815943 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: indirect calorimetry
Description: will be performed every hour throughout the protocol along with exhaled breath collection
Study NCT01022112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-Low
Description: TA-7284-Low
Study NCT01022112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-Low-middle
Description: TA-7284-Low-middle
Study NCT01022112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-High-middle
Description: TA-7284-High-middle
Study NCT01022112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-High
Description: TA-7284-High
Study NCT01022112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05031715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine Phytosome
Description: 2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
Study NCT00635128 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-Polio
Description: A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
Study NCT03330626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InBody group
Description: As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
Study NCT03330626 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IO group
Description: Fluid removal are guided by intake-output balance.
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered intravenous infusion
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously on Day 1 of each 21-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously on Day 1 of each 21-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Study NCT01803282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
Study NCT05196490 — intervention group
Intervention type: DEVICE
Intervention: Micro-CT
Description: Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.
Study NCT05196490 — intervention group
Intervention type: DEVICE
Intervention: CAD/CAM
Description: CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
Study NCT00762775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
Study NCT00762775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
Study NCT01743989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Study NCT04323540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implantitis reconstructive surgery
Description: For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.
Study NCT04323540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-implantitis reconstructive surgery
Description: For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.
Study NCT01807000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled Prucalopride Succinate
Description: A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
Study NCT02215525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA
Description: device uses UVA
Study NCT02215525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal
Description: Herbal tablets, 1000 mg every 6 hours daily for 6 months
Study NCT01741103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100mg by mouth once a day for 12 weeks
Study NCT01741103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one by mouth daily for 12 weeks
Study NCT01169922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION
Description: 2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
Study NCT01169922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INFORMATION-ONLY SEXUAL RISK REDUCTION
Description: 1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
Study NCT03636191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic strain
Description: Lactobacillus
Study NCT03636191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01060839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single session counseling
Description: For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
Study NCT01453400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
Description: Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
Study NCT01453400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen + placebo
Description: Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
Study NCT01453400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
Study NCT01805752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-shifting to lower-cadre providers at PMTCT sites
Study NCT01805752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POC CD4+ cell count testing
Study NCT01805752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated mother-infant care
Study NCT01805752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prominent role for influential family members (male partners) in collaboration with CHWs
Study NCT00854893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area